Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Masayuki Tanaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0335-3912; OpenAlex author ID A5079443873. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
112
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 5 papers · 2025: 2 papers · 2026: 4 papers

Papers 22

  1. Impact of Sarcopenia During Induction Treatment in Patients With Unresectable Locally Advanced Pancreatic Cancer. First author DOI 10.1002/ags3.70078↗
  2. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  3. Postoperative risk stratification after upfront surgery for resectable pancreatic ductal adenocarcinoma in the S-1 adjuvant era. First author DOI 10.1016/j.pan.2026.05.008↗
  4. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  5. Clinical Impact of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Study. Co-author DOI 10.1245/s10434-024-16851-z↗
  6. Pancreatic Cancer Mimicking Relapse of Autoimmune Pancreatitis: Case Reports. Co-author DOI 10.70352/scrj.cr.25-0076↗
  7. Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-72569-8↗
  8. Prognosis prediction of PDAC via detection of O-glycan altered extracellular vesicles in perioperative sera. Co-author DOI 10.1111/cas.16341↗
  9. Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study. Co-author DOI 10.1186/s12957-024-03609-w↗
  10. Efficacy and safety of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4671932/v1↗
  11. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Co-author DOI 10.3892/ol.2024.14272↗
  12. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: A case report. Co-author DOI 10.1097/md.0000000000035856↗
  13. Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis. Co-author DOI 10.1245/s10434-022-12569-y↗
  14. ASO Author Reflections: Prediction of the Chemotherapy Effect on the Prognosis of Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12579-w↗
  15. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  16. Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. Co-author DOI 10.3748/wjg.v27.i3.294↗
  17. Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04203-2↗
  18. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. Co-author DOI 10.1016/j.hpb.2019.06.012↗
  19. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Co-author DOI 10.1002/bjs.11295↗
  20. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Co-author DOI 10.1016/j.ejso.2019.03.039↗
  21. Techniques for splenic vein reconstruction after pancreaticoduodenectomy with portal vein resection for pancreatic cancer. First author DOI 10.1016/j.hpb.2019.01.017↗
  22. Asymptomatic Pancreatic Cancer: Does Incidental Detection Impact Long-Term Outcomes? Co-author DOI 10.1007/s11605-017-3421-2↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shutaro Hori · 11 shared papers, 2021–2026 · strength 2.28
  2. Minoru Kitago · 11 shared papers, 2021–2026 · strength 2.28
  3. Yuta Abe · 11 shared papers, 2021–2026 · strength 2.28
  4. Yutaka Nakano · 10 shared papers, 2021–2026 · strength 2.05
  5. Yohei Masugi · 7 shared papers, 2021–2025 · strength 1.29
  6. Yuko Kitagawa · 6 shared papers, 2021–2026 · strength 1.15
  7. Thilo Hackert · 6 shared papers, 2019–2023 · strength 1.01
  8. Yuko Kitagawa · 4 shared papers, 2024–2025 · strength 0.83
  9. Gaku Shimane · 4 shared papers, 2024–2025 · strength 0.79
  10. Sho Uemura · 3 shared papers, 2024–2026 · strength 0.69
  11. Yosuke Inoue · 5 shared papers, 2017–2026 · strength 0.56
  12. Markus Wolfgang Büchler · 4 shared papers, 2019–2023 · strength 0.50
  13. Ulla Klaiber · 4 shared papers, 2019–2023 · strength 0.50
  14. Ulrike Heger · 4 shared papers, 2019–2023 · strength 0.50
  15. André L. Mihaljević · 3 shared papers, 2019–2023 · strength 0.40
  16. Max Heckler · 3 shared papers, 2019–2023 · strength 0.40
  17. Satoshi Hirano · 2 shared papers, 2026 · strength 0.38
  18. Tsutomu Fujii · 2 shared papers, 2026 · strength 0.38
  19. Yu Takahashi · 4 shared papers, 2017–2022 · strength 0.37
  20. Hiroshi Nishihara · 2 shared papers, 2024 · strength 0.37
  21. Eisuke Iwasaki · 2 shared papers, 2021–2025 · strength 0.34
  22. Hideaki Kojima · 2 shared papers, 2021–2025 · strength 0.34
  23. Satoru Matsuda · 1 shared paper, 2026 · strength 0.30
  24. Kohei Mishima · 1 shared paper, 2026 · strength 0.30
  25. Sohei Satoi · 2 shared papers, 2022–2026 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.